Apolo, A. B., Ballman, K. V., Sonpavde, G., Berg, S., Kim, W. Y., Parikh, R., Teo, M. Y., Sweis, R. F., Geynisman, D. M., Grivas, P., Chatta, G., Reichert, Z. R., Kim, J. W., Bilen, M. A., McGregor, B., Singh, P., Tripathi, A., Cole, S., Simon, N., Niglio, S., Ley, L., Cordes, L., Srinivas, S., Huang, J., Odegaard, M., Watt, C., Petrylak, D., Hoffman-Censits, J., Wen, Y., Hahn, O., Mitchell, C., Tan, A., Streicher, H., Sharon, E., Moon, H., Woods, M., Halabi, S., Burbano, G. P., Morris, M. J., Rosenberg, J. E. (2025). Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2401726